Wednesday, March 1, 2017

BRIEF-Sangamo Therapeutics receives orphan drug designation from the FDA for SB-913 genome editing treatment for MPS II

* Sangamo Therapeutics receives orphan drug designation from

the fda for sb-913 genome editing treatment for mps ii

Read more

No comments:

Post a Comment